Pharmaceutical Executive, Jul 1, 2011 - Pharmaceutical Executive

ADVERTISEMENT

Pharmaceutical Executive, Jul 1, 2011
Features
Planning Beyond the Petri Dish
By William Looney
Pfizer's crizotinib development program combined organization, art, and science—and a large dose of unforeseen risk
Cancer: From Rut to Racetrack
By Natalie Dickmeyer , Lindsay Rosenbeck
The objective is to make most cancers a curable, chronic condition. But with soaring costs, crowded therapeutic competition, and new diagnostic reimbursement challenges ahead, can industry deliver?
Precious Mettle
By Ben Comer
Taking Onyx Pharmaceuticals to new heights – CEO Tony Coles talks to PharmExec about the midsize company's transition from adolescence to adulthood.
What the 2011 Census of India Reveals for Pharma
By Mangesh Sai
What India's latest census tells us about current and future pharma opportunities.
From the Editor
Truth Found in the Wrong Places
By William Looney
More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them
Columns
Battles over Biosimilars
By Jill Wechsler
Sponsors must handle interchangeability, exclusivity, cost and coverage hurdles to win biosimilars game
New Ways to Gain New Brand Insights
By Bronwen Clark , Ellen Cabacungan
If you can learn to understand patient and physician behavior, you are well on your way to strengthening the position of your product
How to Prevent a Facebook Faux Pas
By Ben Comer
'Like' and 'Dislike' practices in the virtual Facebook pharmaceutical world.
10 Emergency Brand Building Questions
By Al Topin
EAB Member Al Topin delivers 10 questions that should drive your brand-building marketing program.
Holy Surge of Enthusiasm!
By Reflector
While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy
Seeing the Fire Behind the Smoke
By Todd C. Davis
Structuring a good deal depends on understanding your partner—and a high degree of specificity

ADVERTISEMENT

Click here